Authors' recommendations: Diabetes affects 25.8 million people in the United States, with a projected worldwide prevalence of 340 million by 2030 according to the World Health Organization (WHO). Individuals with diabetes have elevated blood glucose levels due to impaired insulin production and/or insulin resistance. Approximately 90% of affected individuals have type 2 diabetes (T2D). T2D is associated with other common conditions, including obesity and cardiovascular disease; and chronic hyperglycemia can result in complications such as chronic kidney disease, retinopathy, neuropathy, and poor circulation in extremities, resulting in amputation. The cost of care due to diabetes was estimated at $174 billion in 2007, with $116 billion as a result of direct medical costs. Glucose-based measurements, including fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), and 2-hour plasma glucose during an oral glucose tolerance test (OGTT), are the most widely used tests to diagnose diabetes and assess risk of developing diabetes. Currently, there are a number of medications to treat T2D. Insulin, sulfonylureas, metformin, and thiazolidinediones are the most commonly prescribed medicines, and more recently, two Food and Drug Administration (FDA)- approved drugs (Symlin® and Byetta®; Amylin Pharmaceuticals Inc.) have entered the market. In addition to drug therapies to reduce T2D, nonpharmacological lifestyle and dietary interventions resulting in weight loss have resulted in reduction in incident T2D. To prevent diabetes, predicting disease development during a prediabetes stage may reduce the health and economic burden of this condition. Therefore, in addition to glucose-based methods of risk prediction, many new diagnostic tests have been developed over the past decade. Genomics, proteomics, and metabolomics information is being used in risk models, and in many cases, multiple-component tests are also being developed to improve diabetes risk prediction. This report assesses the PreDx® Diabetes Risk Score (DRS) test, a multiple-biomarker test to identify high-risk individuals who might develop diabetes within 5 years.

Project Status: Completed

Year Published: 2012

URL for published report: The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=14501

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: United States

Organisation Name: HAYES, Inc.

Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218

Contact Name: saleinfo@hayesinc.com

Contact Email: saleinfo@hayesinc.com

Copyright: 2013 Winifred S. Hayes, Inc